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e under theAbstract Approximately 17.3 million people died from cardiovascular disease
(CVD) in 2008, and approximately 80% came from low- and middle-income countries.
However, previous studies document poor research productivity related to CVD pre-
vention and treatment in these countries between 1991 and 1996. The World Health
Organization (WHO) developed a prioritized research agenda emphasizing research
on policy development, translation of knowledge and implementation. This study
assessed whether research output in priority areas increased between 2002 and
2011. It was reported that only 3–4% of papers from each year related to a priority
area, and most were conducted by corresponding authors from high-income coun-
tries. Low-income countries were highly underrepresented both in terms of produc-
tivity and as the study population. However, there was a significant rise in the
productivity of middle-income countries and their representation as the study pop-
ulation. While 30% of priority-related papers addressed a cost-effective strategy,
this represents 1% of papers overall. More cost-effectiveness research is encouraged
to decrease the millions of deaths per year attributed to CVD in the developing
world.
ª 2013 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Cardiovascular diseases (CVDs) refer to coronary
artery disease, cerebrovascular disease, peripheral
vascular disease, rheumatic heart disease, congen-3
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CC BY-NC-ND license (http://ital heart disease, deep vein thrombosis and pul-
monary vascular disease. Collectively, these
seven diseases are the number one cause of death
globally [1]. A report from the World Health Orga-
nization (WHO) estimates that 17.3 million people
died from CVDs in 2008, and 80% of these cases oc-
curred in low- and middle-income countries [2]. It
is thought that people in resource-poor countries
have less access to preventive services, less access
to medications and procedures, and more exposure
to risk factors such as tobacco exposure andabia. Published by Elsevier Ltd.
creativecommons.org/licenses/by-nc-nd/4.0/).
24 L. Myers, S. Mendisfat-laden foods. Unfortunately, this means that
countries with the fewest resources to conduct re-
search on risk factors and cost-effective interven-
tions carry the burden of disease.
While some treatments for these diseases are
expensive (CABG, stenting, valve replacements,
and pacemakers), many are affordable to all coun-
tries (aspirin, insulin, generic anti-hypertensives,
generic statins, and nicotine replacement). A
systematic review by Shroufi et al. [3] published
in 2013 examined the number and type of cost-
effective interventions for CVDs that were done
in low- and middle-income countries in 2010. These
included both behavioral and pharmacologic
interventions where cost per disability-adjusted
life-year was less than 1-3 times the gross national
income per capita. Of the 9729 papers obtained in
the original search, the list was narrowed to 16
papers that addressed the following four broad cat-
egories: medications to lower blood pressure and
cholesterol [4–14]; tobacco control (through nico-
tine patch, bupropion, and price control of ciga-
rettes) [15,16]; intervention through mass media
(diet modification, reduced salt intake, and smok-
ing cessation) [17,18]; and intervention through
legislation (mandatory lowering of salt added to
mass-produced food) [19]. If a countrys limited re-
sources were allocated to these cost-effective,
data-proven strategies, one could imagine a signif-
icant reduction in the CVD morbidity and mortality
in low- and middle-income countries.
However, these cost-effective strategies need
to be adapted for and validated in specific popu-
lations prior to being implemented broadly. A pa-
per by Mendis et al. [20] documented low CVD
research output from low- and middle-income
countries between 1991 and 1996. They report
that 82 developing countries, which represent
11% of the global population, did not publish a
single paper in their random sample [20]. This
data indicates that the amount of meaningful re-
search that contains outcomes-based data on
cost-effective strategies in low- and middle-in-
come countries must be increased.
This study sought to assess the progress of CVD
research output in the last decade between 2002
and 2011. A sample of a large number of papers
from each year was chosen and it was determined
if they addressed one of the four broad categories
published by the WHO as priority research areas
(Table 1) [21]. The country of origin of the corre-
sponding author and study population, the type of
study, the presence of cost-effective strategies
and the language of publication (Table 2) were ana-
lyzed to get a better sense of the features of thepriority-related papers published during this
timeframe.
2. Materials and methods
Medline was searched using the MeSH term ‘‘Car-
diovascular Diseases’’ and a year filter of 2002
and 2011; 3000 publications from each year in
any language and from any country were examined
by a physician, who read the abstracts and decided
if the topic related at all to a WHO priority area.
The original article was obtained if categorization
was unclear. Each paper was assigned to one prior-
ity area that fit it best. The physician recorded the
country of origin of the corresponding author and
the study population. The World Bank list of econ-
omies from November 2011 was used to classify
these countries by income level.
Fishers Exact test was used to assess statistical
significance in research output over time (Table 1).
It was also used to assess statistical significance in
research output over time with the corresponding
authors from high vs. a combined group of low-
and middle-income countries, and research output
over time studying populations from high vs. a
combined group of low- and middle-income coun-
tries. Papers were classified as being a north to
north collaboration (corresponding author and
study population from a high-income country),
north to south collaboration (corresponding author
from a high-income country and study population
from a middle- or low-income country, respec-
tively), or south to south collaboration (corre-
sponding author and study population from
low- or middle-income country). North to south
and south to south collaborations were compared
with north to north collaborations using Fishers
Exact test (Table 2).
Similarly, Fishers Exact test was used to assess
statistical significance in the type of publication
over time (Table 2). For example, the number of
clinical papers (that were not RCTs or survey-
based) was compared with the combined group of
all other types of publications published over time.
Finally, Fishers Exact test was used to assess sta-
tistical significance for the number of publications
with cost-effective strategies over time and num-
ber published in a language other than English over
time (Table 2).
3. Results and discussion
There were 47,897 cardiovascular disease publica-
tions indexed in 2002 and 54,488 in 2011, which in-
creased overall from 35,000 in 1991 to 39,000 in
Table 2 Characteristics of Priority-area Papers.
2002 (N; %) 2011 (N; %)
Income Level of Country of Origin of Study Population
High income 78; 85% 78; 72% p = 0.03
Middle income 14; 15% 27; 25%
Low income 0 3; 3%
Income Level of Corresponding Authors Country of Origin
High income 83; 90% 83; 77% p = 0.01
Middle income 9; 10% 23; 21%
Low income 0 2; 2%
Collaborations
North author to north study population 78; 85% 78; 72% p = 0.05
North author to south study population 5; 5% 5; 5%
South author to south study population 9; 10% 25; 23%
Type of Publication
Clinical (not randomized or survey-based) 48; 52% 75; 69% p = 0.01
Prevalence or Incidence Surveys 16; 17% 15; 14%
Review (including systematic) 15; 16% 5; 5% p = 0.01
Randomized Controlled Trial (RCT) 3; 3% 4; 4%
Comment 3; 3% 3; 3%
Historical, News or Editorial 3; 3% 3; 3%
Meta-analysis 1; 1% 1; 1%
Case Report 2; 2% 0
Meeting Abstract or Report 1; 1% 0
Practice Guidelines 0 0
Contains a Cost-effective Strategy 3; 3% 5; 5% p = 0.73
Published in Language other than English 8; 9% 13; 12% p = 0.49
Data are shown from 2002 and 2011. The number (N) and percentage (%) of papers are listed. The p-values for study population,
corresponding author and collaborations were calculated by combining low- and middle income groups and north-south and south-
south groups. The p-values for the type of publication were calculated by comparing to a combined group of all other publication
types listed. The p-values for cost-effective strategy and language other than English were calculated by comparing to the number
not including a cost-effective strategy and not published in English, respectively.
Table 1 Distribution of Papers in 20 WHO Priority Areas for NCD Research.
2002 (N; %) 2011 (N; %) p-Value
A Research to placing NCDs in the global development
agenda and for monitoring NCDs and NCD risk factors
40; 44% 51; 47% p = 0.7
B Intersectoral and multidisciplinary research to
understand and influence the macroeconomic and
social determinants of NCDs and exposure to NCD risk
factors
24; 26% 25; 23% p = 0.7
C Translation research and health system research for
global application of proven cost-effective strategies
27; 29% 32; 30% p = 1.0
D Research to enable expensive but effective
interventions to become accessible and used
appropriately in resource constrained settings
1; 1% 0 N/A
Data are shown from 2002 and 2011. Each column contains the number (N) and percentage (%) of papers that related to priority
areas, A–D, on the left.
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pers in each year, a small percentage (only 3% from
2002 and 4% from 2011) related to a WHO priority
area.Of the 3–4% of papers that related to a WHO pri-
ority area, a large percentage addressed priority A,
which identified NCD risk factors, NCD monitoring
and placing of NCD prevention on the global agenda
26 L. Myers, S. Mendis(44% from 2002 and 47% from 2011, Table 1). These
papers were mainly epidemiologic and survey-
based data, and many simply stated the problem
of a growing worldwide prevalence of CVD without
actually testing interventions to curb the growing
incidence. Group B papers identified macroeco-
nomic and social determinants of NCD health,
including exposures to risk factors and the effect
of a tax on tobacco. Group C papers were transla-
tional and health systems research focused on
implementing cost-effective interventions in
resource-poor settings and addressing barriers to
access. Only 1 paper was classified as related to
area D, which addressed implementing expensive
but effective interventions in resource-poor set-
tings, so statistical significance could not be inter-
preted with such a small N (Table 1). The number
of priority-related publications in areas A, B or C
did not rise significantly over time (p = 0.7,
p = 0.7, p = 1, respectively, Table 1). These data
indicate that few papers overall are addressing
the effects of implementing new policies, cost-
effective interventions and alternative healthcare
delivery models, and that the number has not risen
between 2002 and 2011.
Looking more closely at the priority-related
papers, there was a statistically significant rise in
papers studying populations in the combined group
of low- and middle-income countries (p = 0.03,
Table 2), but the contribution of papers studying
low-income countries was persistently low (0%
and 3%, Table 2). In terms of corresponding
authors country of origin, most papers were
published with a corresponding author from a
high-income country (90% in 2002 and 77% in
2011, Table 2). Two countries published a large
portion of these papers. The USA produced 21% of
all priority-related papers in 2002 and 19% in
2011, and the UK produced 21% in 2002 and 12%
in 2011 (Data not shown). Interestingly, the com-
bined output from low- and middle-income coun-
tries doubled over time, which was a statistically
significant change (p = 0.01, Table 2), but the abso-
lute contribution from low-income countries was
still minimal in both years (0% and 2%, Table 2).
The above relationships were further analyzed
by comparing the type of collaboration over time.
There was a barely statistically significant rise in
the combined number of north to south and south
to south collaborations over time compared with
north to north collaborations (p = 0.05, Table 2).
This rise is an important first step in promoting re-
search in the developing world. Regardless of
whether corresponding authors hail from high-in-
come countries or native low- and middle-incomecountries, the goal is to increase ethical CVD re-
search in study populations from the south who
experience the greatest burden of CVD.
The type of publication was also assessed over
time. There was a statistically significant rise in
clinical papers that were not randomized con-
trolled trials (RCT) or survey-based when compared
with a combined group of all other types of prior-
ity-related papers (52–69%, p = 0.01, Table 2).
Conversely, there was a statistically significant de-
crease in reviews that included systematic reviews
(16–5%, p = 0.01, Table 2). The overall contribu-
tion of RCTs was low in each year (3% and 4% of pa-
pers, respectively, Table 2). Of the 7 RCTs in both
years, six were north to north collaborations, while
the remaining one was a south to south collabora-
tion and contained a cost-effective strategy for
BP control in low-income countries (data not
shown). More RCTs, specifically those containing
a cost-effective intervention, are needed to prove
efficacy of a cost-effective intervention in a cer-
tain population.
There was no significant change over time in the
number of papers directly assessing cost-effective
strategies or the number of papers published in a
language other than English (p = 0.73 and
p = 0.49, respectively, Table 2). However, of the
papers published in a language other than English,
a disproportionately high percentage had a corre-
sponding author from middle-income countries
(38% from 2002 and 46% from 2011, data not
shown), which raises the concern that papers pub-
lished in languages other than English are less
accessible to be read and appreciated by the great-
er scientific community.
The limitations of this study include sampling er-
ror and the use of corresponding author to identify
the country of origin of researchers.
4. Conclusions
It is encouraging that research output has in-
creased from middle-income countries between
2002 and 2011 and that populations from middle-
income countries are increasingly the subject of
research. However, low-income countries remain
disproportionately underrepresented for both the
corresponding author and the study population.
There is hope to see more low-income countries
for the study population going forward. As long as
research is performed ethically with the local dis-
ease burden, culture and economy as the focus,
this research encourages both north to south col-
laborations and south to south collaborations. It
is also hoped to see more RCTs so that the effect
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uted to bias.
Furthermore, there is an ongoing need for re-
search on cost-effective CVD prevention and treat-
ment strategies. While 30% of priority-related
papers addressed cost-effective interventions, this
means that 1% of papers overall look at cost-effec-
tive strategies, which is simply insufficient when
paired against the millions of deaths that are
attributed to CVDs per year.
Given the current availability of cost effective
and affordable interventions for CVD, researchers
must find ways to implement them in low- and mid-
dle-income countries and measure the effect of
the interventions. New strategies must also be
developed that are country- and population-
specific to strengthen CVD prevention by improving
access to healthcare either through changes in
local policy or healthcare financing/delivery
models. As a global community, the enormous
potential to save lives and come together to make
a difference must be recognized.
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